Tamibarotene in Newly Diagnosed Acute Myeloid Leukemia (AML)

home / insights / tamibarotene-in-newly-diagnosed-acute-myeloid-leukemia-aml-

Dr Daniel Pollyea comments on the potential use of tamibarotene in patients that are newly diagnosed with acute myeloid leukemia (AML).

Treatment Options for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

EP. 1: Treatment Options for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Daniel Pollyea, MD, MS
June 17th 2022

A review of treatment options for patients with newly diagnosed acute myeloid leukemia and differences between patients who are fit vs unfit for chemotherapy.

Biomarker Testing in AML

EP. 2: Biomarker Testing in AML

Daniel Pollyea, MD, MS
June 17th 2022

Dr Daniel Pollyea comments on biomarker testing in acute myeloid leukemia and the potential role for RARA testing.

Potential Role of Tamibarotene in AML

EP. 3: Potential Role of Tamibarotene in AML

Daniel Pollyea, MD, MS
June 28th 2022

Daniel Pollyea, MD, MS, reviews the initial results from the biomarker-directed phase 2 tamibarotene trial that were presented at ASH 2020.

Venetoclax and HMA Resistance in Patients with AML

EP. 4: Venetoclax and HMA Resistance in Patients with AML

Daniel Pollyea, MD, MS
June 28th 2022

Dr Daniel Pollyea discusses the role of venetoclax plus an HMA agent in patients with AML and talks about some possible mechanisms of resistance to the venetoclax-HMA combination.

Review of the SELECT-AML-1 Trial and the Future of Newly Diagnosed AML

EP. 5: Review of the SELECT-AML-1 Trial and the Future of Newly Diagnosed AML

Daniel Pollyea, MD, MS
July 6th 2022

Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.